Latest Information Update: 26 Aug 2015
At a glance
- Originator Yingu Pharmaceutical
- Class Antiallergics; Small molecules
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Allergic rhinitis